Urogen Pharma (NASDAQ:URGN) Insider Sells $176,900.00 in Stock

Key Points

• Urogen Pharma insider Mark Schoenberg sold 10,000 shares at an average price of $17.69, reducing his stake by 6.32% to 148,229 shares, valued at approximately $2.62 million.
• The company's recent quarterly earnings report showed a loss of ($1.05) EPS, missing analysts' expectations, but revenue of $24.22 million surpassed estimates.
• Analysts remain optimistic about Urogen Pharma, maintaining a consensus "Buy" rating with an average target price of $31.43, despite fluctuations in target prices from various firms.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the sale, the insider owned 148,229 shares in the company, valued at $2,622,171.01. This trade represents a 6.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mark Schoenberg also recently made the following trade(s):

• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The stock was sold at an average price of $19.14, for a total value of $98,551.86.
• On Monday, June 9th, Mark Schoenberg sold 5,162 shares of Urogen Pharma stock. The shares were sold at an average price of $7.37, for a total value of $38,043.94.

Urogen Pharma Stock Performance

NASDAQ:URGN traded down $0.31 during mid-day trading on Monday, reaching $19.40. The stock had a trading volume of 581,893 shares, compared to its average volume of 1,565,284. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.01. The business has a 50 day simple moving average of $15.46 and a 200 day simple moving average of $11.66. The firm has a market capitalization of $897.44 million, a price-to-earnings ratio of -5.84 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The business had revenue of $24.22 million during the quarter, compared to analysts' expectations of $23.06 million. As a group, sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the stock a "neutral" rating in a research report on Friday, June 13th. Guggenheim restated a "buy" rating and issued a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Oppenheimer set a $31.00 target price on shares of Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a report on Tuesday, August 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $31.43.

Institutional Investors Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. CWM LLC increased its holdings in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Urogen Pharma during the fourth quarter worth about $67,000. GAMMA Investing LLC increased its holdings in Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after acquiring an additional 5,571 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Urogen Pharma during the 4th quarter valued at approximately $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.